Fiche publication
Date publication
janvier 2016
Journal
Clinical Medicine Insights. Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BORG Christophe
,
Pr NERICH Virginie
,
Dr KIM Stephano
,
Dr LAKKIS Zaher
Tous les auteurs :
Calcagno F, Lenoble S, Lakkis Z, Nguyen T, Limat S, Borg C, Jary M, Kim S, Nerich V
Lien Pubmed
Résumé
Regorafenib is an orally administered multikinase inhibitor that has been approved for patients with chemotherapy-refractory metastatic colorectal cancer (mCRC). Even though regorafenib significantly improved survival in two international phase 3 trials (CORRECT and CONCUR), a high rate of treatment-related toxic effects and dose modifications were observed with a modest benefit. The aim of this study was to provide information concerning the efficacy, safety, and cost of regorafenib in patients with mCRC in clinical practice.
Mots clés
cost, efficacy, metastatic colorectal cancer, regorafenib, safety
Référence
Clin Med Insights Oncol. 2016 ;10:59-66
